Eargo faces delisting if it fails to provide Q3 report

US-based hearing aid manufacturer Eargo, which is the center of an investigation concerning potential reimbursement fraud, is now being threatened with delisting by New York stock exchange Nasdaq, as it has yet to file its third quarterly report.

Photo: Eargo / PR

Hearing aid manufacturer Eargo, which is spearheaded by the Dane Christian Gormsen, is once again in hot water.

This time, New York stock exchange Nasdaq has threatened to delist the company should it fail to file the missing third quarterly report for the period that ended on Sep. 30, Eargo reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs